Biogen wins U.S. approval of long acting multiple sclerosis drug

NEW YORK (Reuters) - U.S. health regulators on Friday approved Biogen Idec Inc's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older big-selling Avonex treatment.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news